TY - JOUR
T1 - Survival differences according to baseline characteristics of patient with advanced heart failure treated with levosimendan
AU - Garcia-Peña, Angel Alberto
AU - Mariño, Alejandro
AU - Muñoz-Velandia, Oscar Mauricio
AU - Saa-González, Daniela
N1 - Publisher Copyright:
© The Author(s) 2025. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
PY - 2025/7/20
Y1 - 2025/7/20
N2 - Aims:To assess whether baseline characteristics (age, New York Heart Association functional class, left ventricular ejection fraction, glomerular filtration rate, systolic blood pressure, and N-terminal pro-brain natriuretic peptide) predicted different survival functions in patients with advanced heart failure, treated with intermittent inotropics.Methods:Survival analysis based on a retrospective cohort of patients with advanced heart failure, treated with intermittent infusion of levosimendan and managed at heart failure clinic of the Hospital Universitario San Ignacio, in Bogotá (Colombia). We evaluated which baseline characteristics were associated with worse survival outcomes, using Kaplan–Meier curves and log rank test.Results:Forty-two patients with advanced heart failure were included (mean age: 69.5 ± 13.2 years, 97.6% New York Heart Association III–IV, 54.7% of the population had quadruple therapy). A total of 39.5% died during 1-year follow-up. Survival functions were worse in patients with N-terminal pro-brain natriuretic peptide levels >6000 pg/mL (HR: 2.72; 95% CI: 1.01–8.01, p = 0.0493). In contrast, no significant difference in mortality was found for those with basal GFR <60 versus ⩾60 ml/min (p = 0.1030), left ventricular ejection fraction ⩽20% versus >20% (p = 0.1040), systolic blood pressure <90 mmHg versus ⩾90 mmHg (p = 0.2463), according to functional class (p = 0.840) or age > 65 years (p = 0.169). A significant increase of left ventricular ejection fraction measurements was observed in 26 surviving patients at 12 months of follow-up (20% vs 34%, p < 0.0001).Conclusion:Our preliminary data suggest that the only characteristic that could predict worse survival in patients with advanced heart failure treated with levosimendan is N-terminal pro-brain natriuretic peptide levels greater than 6000 pg/ml. Future research is needed to confirm our findings.
AB - Aims:To assess whether baseline characteristics (age, New York Heart Association functional class, left ventricular ejection fraction, glomerular filtration rate, systolic blood pressure, and N-terminal pro-brain natriuretic peptide) predicted different survival functions in patients with advanced heart failure, treated with intermittent inotropics.Methods:Survival analysis based on a retrospective cohort of patients with advanced heart failure, treated with intermittent infusion of levosimendan and managed at heart failure clinic of the Hospital Universitario San Ignacio, in Bogotá (Colombia). We evaluated which baseline characteristics were associated with worse survival outcomes, using Kaplan–Meier curves and log rank test.Results:Forty-two patients with advanced heart failure were included (mean age: 69.5 ± 13.2 years, 97.6% New York Heart Association III–IV, 54.7% of the population had quadruple therapy). A total of 39.5% died during 1-year follow-up. Survival functions were worse in patients with N-terminal pro-brain natriuretic peptide levels >6000 pg/mL (HR: 2.72; 95% CI: 1.01–8.01, p = 0.0493). In contrast, no significant difference in mortality was found for those with basal GFR <60 versus ⩾60 ml/min (p = 0.1030), left ventricular ejection fraction ⩽20% versus >20% (p = 0.1040), systolic blood pressure <90 mmHg versus ⩾90 mmHg (p = 0.2463), according to functional class (p = 0.840) or age > 65 years (p = 0.169). A significant increase of left ventricular ejection fraction measurements was observed in 26 surviving patients at 12 months of follow-up (20% vs 34%, p < 0.0001).Conclusion:Our preliminary data suggest that the only characteristic that could predict worse survival in patients with advanced heart failure treated with levosimendan is N-terminal pro-brain natriuretic peptide levels greater than 6000 pg/ml. Future research is needed to confirm our findings.
KW - Advanced heart failure, levosimendan, mortality, NT pro-BNP, functional class and left ventricular ejection fraction
KW - Advanced heart failure
KW - levosimendan
KW - mortality
KW - NT pro-BNP
KW - functional class and left ventricular ejection fraction
UR - https://doi.org/10.1177/20503121251357357
UR - https://www.mendeley.com/catalogue/75add470-6a0e-3ec8-a976-bdb9b36275be/
UR - https://www.scopus.com/pages/publications/105012561421
U2 - 10.1177/20503121251357357
DO - 10.1177/20503121251357357
M3 - Article
C2 - 40689263
SN - 2050-3121
VL - 13
JO - SAGE Open Medicine
JF - SAGE Open Medicine
M1 - 20503121251357357
ER -